

NCCN Guidelines for Esophageal and Esophagogastric Cancer V.3.2022 Follow-up on 06/13/22

| Guideline Page and Request | Panel Discussion/References | Vote | | | |
|--|--|------|----|---------|--------|
| | | YES | NO | ABSTAIN | ABSENT |
| ESOPH-F Page 3 External request Submission from Bristol Myers Squibb (05/31/22) requesting that the panel consider the inclusion of nivolumab in combination with ipilimumab as a Category 1 first-line treatment option for patients with unresectable advanced, recurrent or metastatic ESCC (ESOPH-F, page 3 of 17) | Based on the review of the data in the noted reference, the panel consensus was to include nivolumab in combination with ipilimumab as a first-line treatment option for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This is a category 2A, preferred recommendation. | 18 | 1 | 3 | 10 |
| | The panel consensus did not support a category 1 recommendation. | 13 | 3 | 6 | 10 |
| | Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. <i>N Engl J Med</i> . 2022;386(5):449-462. | | | | |
| ESOPH-F Page 3 External request Submission from Bristol Myers Squibb (05/31/22) requesting that the panel consider: the inclusion of nivolumab in combination with chemotherapy as a Category 1 first-line treatment option for patients with unresectable advanced, recurrent or metastatic ESCC (ESOPH-F, page 3 of 17) | Based on the review of the data in the noted reference, the panel consensus was to make the following changes: | | | | |
| | <ul style="list-style-type: none"> The panel consensus was to include fluoropyrimidine (fluorouracil or capecitabine), OXALIPLATIN, and nivolumab as a first-line treatment option for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This is a category 2B, preferred recommendation. <ul style="list-style-type: none"> The panel consensus did not support a category 1 recommendation. | 15 | 4 | 3 | 10 |
| | | 11 | 5 | 6 | 10 |
| | <ul style="list-style-type: none"> The panel consensus was to include fluoropyrimidine (fluorouracil or capecitabine), CISPLATIN, and nivolumab as a first-line treatment option for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This is a category 2B, preferred recommendation. <ul style="list-style-type: none"> The panel consensus did not support a category 1 recommendation. | 15 | 4 | 3 | 10 |
| | | 12 | 4 | 6 | 10 |
| See submission for references | | | | | |

NCCN Guidelines for Esophageal and Esophagogastric Cancer V.3.2022 Follow-up on 06/13/22

| | | | | | |
|--|---|---|----|---|----|
| <p>External request</p> <p>Submission from Bristol Myers Squibb (09/24/21 and 01/26/22) requesting that nivolumab in combination with chemotherapy be recommended as a category 1 first-line treatment option for patients with advanced or metastatic gastroesophageal junction cancer, and esophageal adenocarcinoma regardless of PD-L1 combined positive score (CPS), which is consistent with the FDA-approved indication (effectively changing the recommendations for patients with PD-L1 CPS < 5 from “category 2B” to “category 1” on page ESOPH-F [3 of 17]).</p> | <p>Based on a review of the data and discussion, the panel consensus did not support revising the guidelines as follows:</p> <ul style="list-style-type: none"> • Include Fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, and nivolumab as a first-line treatment option for unresectable locally advanced, recurrent, or metastatic esophageal or EGJ adenocarcinoma regardless of PD-L1 combined positive score (CPS) <ul style="list-style-type: none"> ○ The panel consensus did not support a category 1 recommendation. • Include Fluoropyrimidine (fluorouracil or capecitabine), cisplatin, and nivolumab first-line treatment option for unresectable locally advanced, recurrent, or metastatic esophageal or EGJ adenocarcinoma regardless of PD-L1 combined positive score (CPS). <ul style="list-style-type: none"> ○ The panel consensus did not support a category 1 recommendation. <p>See Submissions for references</p> | 9 | 9 | 4 | 10 |
| | | 4 | 12 | 6 | 10 |
| | | 7 | 10 | 5 | 10 |
| | | 3 | 12 | 7 | 10 |